EUCTR2008-001645-26-IT进行中（未招募）不适用
Phase II study: Systemic treatment with alternating weekly regimen of temozolomide and monthly fotemustine combination in recurrent glioblastoma patients. - ND
ISTITUTO NEUROLOGICO CARLO BESTA0 个研究点开始时间: 2008年6月30日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study: 1.Signed and dated IRB-approved Informed Consent. 2.Histologically proven (at diagnosis) Glioblastoma Multiforme (GBM) 3.Recurrence or progression after treatment with surgery, radiotherapy and chemotherapy, including temozolomide 4.Age more between 18 years 5.KPS 18 and 70 years enclosed 6.Life expectancy of at least 12 weeks 7.Negative pregnancy test (if female in reproductive age) 8.Agreement upon the use of effective contraceptive methods (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation, if men and women of child-producing potential 9.Acceptable liver function: - Bilirubin 1.5 upper limit of normal (ULN) - Albumin 3.0 g/dL - AST (SGOT), ALT (SGPT) 2.5 ULN (if liver metastases are present, then 5 ULN is allowed) - Alkaline phosphatase 2.5 ULN (if liver and/or bone metastases are present, then 5 ULN is allowed) 10.Acceptable renal function: Serum creatinine ≤1.5 mg/dl (or ≤133 µmol/L) 11.Acceptable hematologic status: - ANC 1,500 cells/mm3 - Platelet count 100,000 cells/mm3 - Hemoglobin 10.0 g/dL 12.At the time of first dose of study combination, at least 4 weeks must have elapsed since completion of prior temozolomide therapy, prior radiotherapy, prior surgery (at least 6 weeks since completion of prior nitrosurea therapy) 13.With the exception of alopecia, resolution of all acute toxic effects of any prior surgery, radiotherapy, radiosurgery or chemotherapy to NCI CTC (Version 3.0) Grade < 1 and to the baseline laboratory values as defined in Inclusion Criteria Number 9, 10, 11. 14.All patients on treatment with anticonvulsants, should continue the anticonvulsant therapy with non-enzyme-inducing anticonvulsants (non-EIACs) 15.Concurrent steroids allowed, dose stable for at least 7 days before study entry 16.Able and willing to comply with scheduled visits, therapy plans, and laboratory tests required in this protocol 17.Presence of at least one 1.5 cm2 bi-dimensionally measurable lesion by gadolinium (Gd)-enhanced MRI scan, indicating progressive or recurrent disease, obtained at least 12 weeks after standard external-beam radiotherapy and within 14 days prior to treatment. 18.Patients in relapse, following 1st line chemotherapy including temozolomide.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •The presence of any of the following will exclude a subject from study enrollment: 1.Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1 2.Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy 3.Pregnant or breast feeding women 4.Known infection with HIV, active hepatitis B or hepatitis C 5.Prior high-dose chemotherapy with bone marrow or stem cell support 6.Previous (within the last 5 years) or current malignancies at other sites, except for adequately treated basal cell or squamous cell skin cancer or in situ carcinoma of the cervix uteri. 7.Current enrollment in another therapeutic clinical trial 8.Patients who have exhibited allergic reactions to temozolomide or fotemustine 9.Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgement of the investigator, would make the patient inappropriate for entry into this study.
研究者
相似试验
已完成
2 期
A phase II study of TAS-102 and RamucirumabJPRN-jRCT2080224529Taiho Pharmaceutical Co., Ltd.60
已完成
2 期
Phase II study comparing combination therapy with carboplatin plus pemetrexed vs combination therapy with pemetrexed plus bevacizumab in chemo-naive elderly patients with advanced non-squamous non-small-cell lung cancer (HSR1402).advanced non-squamous non-small-cell lung cancerJPRN-UMIN000014302Hamamatsu Univ. School of Medicine64
进行中（未招募）
不适用
A Phase 2 Study of combined modality treatment with primary chemotherapy followed by endoscopic laser resection in intermediate stage laryngeal squamous cell carcinoma.SQUAMOUS CELL CARCINOMA OF THE LARYNGXMedDRA version: 6.1Level: PTClassification code 10018395EUCTR2005-001132-72-ITISTITUTO EUROPEO DI ONCOLOGIA42
已完成
2 期
Phase II clinical trial of combination therapy with medium-chain triglycerides and ghrelin in patients with chronic obstructive pulmonary diseaseCOPDJPRN-UMIN000015222ational Hospital Organization Toneyama National Hospital10
招募中
不适用
Clinical study of the treatment using alternating magnetic fields (AT-04) for chronic pelvic pain associated with endometriosisChronic pelvic painpelvic painD017699JPRN-jRCT1032220141Kohzo Aisaka10